<DOC>
	<DOC>NCT00508833</DOC>
	<brief_summary>This study was done to evaluate the effect of various adjuvants in combination with HBsAg as a model antigen on the induction of immune responses, mainly cytotoxic T lymphocytes (CTL) in healthy volunteers. The study was also done to evaluate the safety and reactogenicity of the various adjuvanted vaccines.</brief_summary>
	<brief_title>Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Healthy volunteers between 18 and 40 years of age Written informed consent obtained from subject Female of nonchildbearing potential Any hepatitis B vaccination. Positive HBV serological markers: antiHBs, antiHBc, and/ or HBsAg Pregnancy or lactating female Use of any investigational or nonregistered drug or vaccine other than the study vaccine within 30 days or 7 halflives (whichever is the longer) preceding the first vaccine administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Adjuvants</keyword>
	<keyword>HBsAg</keyword>
</DOC>